Format

Send to

Choose Destination
Oncoimmunology. 2015 Jan 7;3(12):e974392. eCollection 2014 Dec.

Mutant IDH1: An immunotherapeutic target in tumors.

Author information

1
DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology; German Cancer Research Center ; Heidelberg, Germany ; Department of Neurooncology; University Hospital Heidelberg ; Heidelberg, Germany.
2
DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology; German Cancer Research Center ; Heidelberg, Germany ; DKTK Clinical Cooperation Unit Neurooncology; German Cancer Research Center ; Heidelberg, Germany.

Abstract

The discovery of driver mutations in cancers has raised interest in their suitability as immunotherapeutic targets. A recent study demonstrates that a point mutation in isocitrate dehydrogenase 1 (IDH1R132H), expressed in gliomas and other tumors, is presented on human MHC class II and induces a mutation-specific CD4+ antitumor T cell response in patients and a syngeneic tumor model in MHC-humanized mice.

KEYWORDS:

IDH1 mutation; MHC class II epitope; MHC-humanized mice; cancer immunotherapy; glioma; mutation-specific CD4+ T-cells

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center